More Web Proxy on the site http://driver.im/

From PGF(2alpha)-isopropyl ester to latanoprost: a review of the development of xalatan: the Proctor Lecture

Invest Ophthalmol Vis Sci. 2001 May;42(6):1134-45.

Author

J W Stjernschantz¹

Affiliation

¹ Department of Neuroscience, Unit of Pharmacology, Box 593, Uppsala University, S-751 24 Uppsala, Sweden. johan.stjernschantz@neuro.uu.se

PMID: 11328719

No abstract available

Publication types

Review

MeSH terms

Animals
Antihypertensive Agents* / adverse effects
Antihypertensive Agents* / chemistry
Antihypertensive Agents* / pharmacology
Antihypertensive Agents* / therapeutic use
Awards and Prizes
Dinoprost* / adverse effects
Dinoprost* / analogs & derivatives*
Dinoprost* / chemistry
Dinoprost* / pharmacology
Dinoprost* / therapeutic use
Glaucoma / drug therapy
Humans
Intraocular Pressure / drug effects*
Latanoprost
Melanosis / chemically induced
Molecular Structure
Ophthalmology
Prostaglandins F, Synthetic* / adverse effects
Prostaglandins F, Synthetic* / chemistry
Prostaglandins F, Synthetic* / pharmacology
Prostaglandins F, Synthetic* / therapeutic use
Respiratory System / drug effects
Societies, Scientific

Substances

Antihypertensive Agents
Prostaglandins F, Synthetic
prostaglandin F2 isopropyl ester
Latanoprost
Dinoprost